Ben Naccarato
Analyst · MHB Capital. Please proceed with our question
Thank you, Lou. Starting with revenue, our total revenue from continuing operations for the first quarter was $10 million compared to last year’s first quarter of $13.6 million, a decrease of $3.6 million or 26.2%. The decrease in revenue was the result of the shortfalls in both our operating and -- in both of our operating segment. Timing delays of waste shipments in the treatment segment resulted in both, lower volume at our waste treatment facilities, as well as the lower average price related to revenue mix. Revenue from the services segment was impacted by the completion of certain large contracts and the delay in the start-up of the new projects. Turning to cost of goods sold, our total cost of sales was $10 million in the first quarter compared to $12.1 million in the prior year. Our treatment segment cost of sales was down by $1.2 million, as a result of the lower volume of waste treated and reduced fixed costs of $361,000. Costs of sales from the service segment were down $946,000 from year, reduced project revenue resulted in low related project expenses. Our gross profit for the quarter was $34,000 compared to $1.5 million in 2015. Gross profit in our treatment segment decreased by $1.4 million compared to prior year. Our facilities carried a relatively large fixed cost burden and the lower revenue such as we had in the first quarter, failed to produce the incremental profit to cover these costs, so the negative gross profit out of our treatment facilities. Similarly, low revenue in the services segment resulted in a minimal gross profit. Our SG&A costs for the quarter were $3.1 million, up from $2.8 million last year. We had increased marketing, and bid and proposal type expenses, which offset a reduction in our administrative cost related to lower consulting and professional services. Our loss from continuing operations for the quarter before taxes was $3.8 million compared to $2 million last year. Included in these costs are costs of $438,000 and $395,000 related to our medical isotopes segment for Q1 ‘16 & ‘15 respectively. Our loss applicable to common shareholders was $3.8 million compared to last year’s net loss of $2.1 million. Again, included in these losses are costs of $438,000 and $395,000 related to the medical isotopes segment for Q1 ‘16 and ‘15 respectively. Our total loss per share for the quarter was $0.33 compared to the loss of $0.18 in the prior year. Our adjusted EBITDA from continuing operations, as defined in this morning’s press release, was a loss of $2.3 million compared to a loss of $441,000, last year. Turning to the balance sheet, our cash was down $736,000, primarily from debt payments, totaling $783,000. Our current receivables, both billed and unbilled were down $2.6 million as a result of lower revenue in the quarter. Our waste backlog was $4.9 million compared to $4.7 million at year end and $6.4 million in March of ‘15. Our current debt excluding our debt issuance costs was $1.8 million down $626,000 from year end and lower than prior year’s first quarter by $1.9 million. Our total debt again excluding debt issuance costs at quarter end were $9.2 million, $8.6 million of which is from our PNC lender and 600,000 from a shareholder loan. Finally, I’ll summarize our cash flow activity in the first quarter. Our cash provided by continuing operations was $251,000; our cash used by discontinued operations was $184,000; cash used in investing was $24,000 of which $9,000 is for capital spending; and cash from financing was $719,000. Finally, I’m going to address our notification of late filing of our Form 10-Q. As covered in our covenanting in our credit facility requires the Company to maintain a fixed charge ratio of 115 to 1 to remain in compliance. We failed to achieve this in the first quarter due in part to the aforementioned delays impacting our top line revenue. We’re in discussions to receive a waiver from our lender for this breach. Unfortunately, our bank was unable to finalize the waiver prior to the filing deadline, requiring us to file the extension. We do expect to receive this waiver prior to the end of the extension period at which time we’ll file our 10-Q. Additionally, our amendment to our loan agreement signed March 24, 2016, significantly reduced our monthly loan payment, which will help in maintaining this covenant in the future. With that, operator, I’ll now open the call to questions.